Q-Med Launches Modified Sodium Hyaluronate In China
This article was originally published in PharmAsia News
Executive Summary
Swedish-based Q-Med has launched its modified sodium hyaluronate for injection in China. After five years of clinical trial and investigation, the product received approval from China's State FDA at the end of last year. It represents the only approved hyaluronic acid filler for cosmetic and plastic surgery purposes in the country. Q-Med has marketed the subcutaneous filler in more than 70 countries and regions worldwide, including the U.S., Canada, Australia, India, Korea and Singapore, safely treating 10 million cases. (Click here for more - Chinese Language)